2024-02-06T09:03:32-06:00 2021-12-31 HAN GROUP LLC 1020 19TH STREET NW SUITE 800 WASHINGTON DC 20036 990 2021-01-01 455312680 LYSOSOMAL AND RARE DISORDERS RESEARCH AND TREATMENT CENTER INC LYSO 7032616220 3702 PENDER DRIVE 170 FAIRFAX VA 22030 UYENSA BEESE TREASURER 7032616220 2024-02-05 UYENSA BEESE 999009999 JENNIFER S HAN P00633304 2022977000 2024-02-05 0 AAL1 IAL1 2021 2023-04-26 12:10:37Z DR OZLEM GOKER-ALPAN 3702 PENDER DRIVE 170 FAIRFAX VA 22030 2664551 0 X WWW.LYSOSOMALCENTER.ORG X 2012 DE RESEARCH AND UNRAVEL DISEASE CAUSING MECHANISMS AND EXPLORE NEW BIOMARKERS AND TREATMENT OPTIONS. 4 0 18 2 0 0 308000 420410 1626009 2243720 0 0 471 421 1934480 2664551 0 0 0 0 1390943 1401064 0 0 0 810969 692245 2201912 2093309 -267432 571242 834123 1635612 740274 958300 93849 677312 X LYSOSOMAL AND RARE DISORDERS RESEARCH AND TREATMENT CENTER INC'S (LDRTC) MISSION IS TO PROVIDE RESEARCH TO UNRAVEL UNDERLYING DISEASE-CAUSING MECHANISMS, DISCOVER NEW BIOMARKERS AND EXPLORE NEW THERAPEUTIC PATHWAYS AND TREATMENT OPTIONS. FURTHER, LDRTC WORKS TO EDUCATE PATIENTS, FAMILIES, HEALTHCARE PROVIDERS AND RESEARCHERS IN THE FIELD. FINALLY, IT PROVIDES TREATMENT AND CLINICAL CARE TO PERSONS SUFFERING FROM LYSOSOMAL AND OTHER RARE DISEASES. 0 0 1234187 TREATMENT & CLINICAL CARE: IN LDRTC'S CLINIC, LDRTC OFFERS EXTENSIVE MEDICAL GENETIC EVALUATIONS FOR COMPLEX MEDICAL PROBLEMS OF UNKNOWN ETIOLOGY AND THAT DO NOT FIT A PARTICULAR DISEASE PATTERN. CASE STUDIES INVOLVING INDIVIDUALIZED THERAPY, INSTITUTIONAL COLLABORATIONS AND INDIVIDUAL BENCH SCIENCE PROJECTS WERE SUCCESSFUL DURING THE PAST YEAR. 564115 RESEARCH: LDRTC AIMS TO BRIDGE THE GAP BETWEEN BASIC AND CLINICAL RESEARCH TO FACILITATE THE DIAGNOSIS, TREATMENT, AND MANAGEMENT OF RARE DISORDERS. LDRTC PRESENTS A UNIQUE TRANSLATIONAL RESEARCH MODEL FOCUSING ON A MULTIDISCIPLINARY APPROACH TO STUDY THE DISEASE PATHOLOGY, WHILE APPLYING CELLULAR, MOLECULAR, AND IMMUNOLOGIC CONCEPTS TO PATHWAYS AMENABLE TO THERAPEUTIC MODULATION. 185922 2243720 EDUCATION: EDUCATION IS FOCUSED AROUND PATIENT MEETINGS, WORKSHOPS, LECTURE SERIES, CONFERENCES, SYMPOSIUMS AND INTERNSHIPS. LDRTC HOLDS VARIOUS WORKSHOPS DESIGNED TO PROVIDE OPPORTUNITIES FOR ITS ATTENDEES TO COLLABORATE AND PROMOTE DISCUSSIONS ON ALL ASPECTS OF LYSOSOMAL BIOLOGY. 1984224 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 17 0 1 18 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 VA X UYENSA BEESE 7032616220 3702 PENDER DRIVE SUITE 170 FAIRFAX VA 22030 DR OZLEM GOKER-ALPAN PRESIDENT/FOUNDER 16.00 X X 345152 0 35499 UYENSA BEESE TREASURER 24.00 X X 64383 0 24850 RENUKA LIMGALA SECRETARY 8.00 X X 42833 0 0 MARGARITA IVANOVA DIRECTOR 8.00 X 93575 0 0 545943 0 60349 1 0 1 0 DR OZLEM GOKER-ALPAN MD 10531 WICKENS ROAD VIENNA VA 22181 CLINICAL RESEARCH SERVICES 170090 1 420410 420410 CLINICAL RESEARCH 541700 1981511 1981511 TRANSLATION RESEARCH 541700 222604 222604 HONORARIUM 900099 30396 30396 PROFESSIONAL LECTURE 900099 9209 9209 2243720 MISCELLANEOUS INCOME 900099 421 421 421 2664551 2243720 0 421 X 606292 606292 483970 483970 27470 27470 283332 281264 2068 2000 2000 6515 6515 250989 240629 10360 5890 589 5301 42262 2610 39652 8421 600 7821 112725 101452 11273 11874 5937 5937 95200 95200 24033 24033 RESEARCH SUPPLIES 73812 73812 CLINICAL RESEARCH SUPP. 33299 33299 TAXES 7047 705 6342 LICENSE & REGIS. 6463 6463 11715 6362 5353 2093309 1984224 109085 0 506038 619904 663281 285393 285393 14804 14805 202045 149816 27888 52229 834123 1635612 26374 44400 713900 913900 740274 958300 X 93849 677312 93849 677312 834123 1635612 571242 12221 0 X 0 0 0 X 829230 2377148 249678 308000 420410 4184466 829230 2377148 249678 308000 420410 4184466 2447032 1737434 471 421 892 4185358 5576644 0.41510 0.99870 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2017 AMOUNT: $ 0. 2018 AMOUNT: $ 0. 2019 AMOUNT: $ 0. 2020 AMOUNT: $ 471. 2021 AMOUNT: $ 421. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15650 15650 0 186395 134166 52229 52229 X X 0 0 0 0 0 0 0 0 0 DR OZLEM GOKER-ALPAN PRESIDENT/FOUNDER 344302 0 850 0 0 0 0 0 35499 0 380651 0 0 0 DR OZLEM GOKER-ALPAN MD FOUNDER/PRESIDENT 170090 LDRTC PROVIDES CLINICAL RESEARCH SERVICES TO DR. OZLEM GOKER-ALPAN, MD MEDICAL PRACTICE. DR. OZLEM GOKER-ALPAN IS THE OWNER OF THE MEDICAL PRACTICE. 0 FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES THAT CAN ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE DRAFT VERSION OF THE FEDERAL FORM 990 IS REVIEWED BY THE FULL BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, AN OFFICER, DIRECTOR, OR EMPLOYEE MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTERESTS IN THE ORGANIZATION, INCLUDING BUSINESS AND FAMILY RELATIONSHIPS IN THE ORGANIZATION. EACH OFFICER, DIRECTOR OF EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE QUESTIONNAIRE ON AN ANNUAL BASIS. ANY POSSIBLE DISCLOSED FINANCIAL INTEREST, OR BUSINESS AND FAMILY RELATIONSHIPS, IS REVIEWED BY THE LDRTC PRESIDENT TO DETERMINE IF A CONFLICT OF INTEREST EXISTS. (NOTE THAT A FINANCIAL INTEREST OR BUSINESS AND FAMILY RELATIONSHIP DOES NOT NECESSARILY CONSTITUTE A CONFLICT OF INTEREST.) IF THE PERSON DISCLOSING THE FINANCIAL INTEREST OR EXISTING BUSINESS AND FAMILY RELATIONSHIPS IS A CURRENT MEMBER OF THE BOARD OF DIRECTORS, SAID MEMBER SHALL LEAVE THE MEETING ROOM DURING THE DISCUSSION OF, AND THE VOTE ON, WHETHER A CONFLICT OF INTEREST EXISTS. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS ESTABLISHES PERFORMANCE METRICS FOR THE CEO. FOLLOWING THE CLOSE OF THE YEAR, THE BOARD OF DIRECTORS REVIEWS THE RESULT TO DETERMINE THE OVERALL LEVEL OF PERFORMANCE. A THIRD-PARTY COMPENSATION CONSULTANT IS ENGAGED TO REVIEW MARKET COMPENSATION FOR THE CEO AND KEY MANAGEMENT EMPLOYEES. THE BOARD OF DIRECTORS PROPOSES CHANGES IN COMPENSATION FOR THE CEO BASED ON PERFORMANCE OUTCOMES. ANY INCREASES IN COMPENSATION FOR KEY MANAGEMENT STAFF ARE PROPOSED BY THE CEO AND APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS AND COPIES OF POLICIES ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G CLINICAL RESEARCH FEES: PROGRAM SERVICE EXPENSES 199,820. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 199,820. 401(K) PLAN FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 10,360. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,360. EMPLOYEE RECRUITING: PROGRAM SERVICE EXPENSES 3,927. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,927. CONSULTING FEES: PROGRAM SERVICE EXPENSES 36,882. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 36,882.